{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:19:43Z","timestamp":1765887583156},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Health and Medical Research Council Career Development Fellowship"},{"name":"Faculty of Health Sciences New Appointment Funding"},{"name":"University of Adelaide, South Australia"},{"name":"Novartis Vaccines and Diagnostics Pty Ltd"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.vaccine.2013.11.042","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T15:40:42Z","timestamp":1385048442000},"page":"338-344","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines"],"prefix":"10.1016","volume":"32","author":[{"given":"Helen","family":"Marshall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2013.11.042_bib0005","first-page":"1061","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial","volume":"31","author":"Marshall","year":"2012","journal-title":"PIDJ"},{"issue":"8","key":"10.1016\/j.vaccine.2013.11.042_bib0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"9869","key":"10.1016\/j.vaccine.2013.11.042_bib0015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2013.11.042_bib0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine ACWY-TT","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv Ther"},{"issue":"9\/10","key":"10.1016\/j.vaccine.2013.11.042_bib0025","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.11.042_bib0030","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0035","series-title":"JCVI interim position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK","author":"Joint Committee on Vaccination and Immunisation","year":"2013"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0040","series-title":"November 2011 PBAC Outcomes \u2013 Positive Recommendations: Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5mL, solution for injection pre-filled syringe single dose, Gardasil\u00ae","author":"Commonwealth of Australia","year":"2011"},{"issue":"3","key":"10.1016\/j.vaccine.2013.11.042_bib0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1467-842X.2007.00054.x","article-title":"A cross sectional survey to assess community attitudes to introduction of human papillomavirus vaccine","volume":"31","author":"Marshall","year":"2007","journal-title":"Aust N Z J Public Health"},{"issue":"6","key":"10.1016\/j.vaccine.2013.11.042_bib0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0055","series-title":"Health omnibus survey methodology brief report: population research and outcomes studies unit","author":"PROS","year":"2012"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0060","series-title":"Socio-Economic Indexes for Areas (SEIFA) \u2013 technical paper, 2006","author":"Australian Bureau of Stastistics","year":"2008"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0065","series-title":"SAS Version 9.3","author":"SAS Institute Inc.","year":"2011"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0070","series-title":"Census of population and housing, 2011 census","author":"Australian Bureau of Statistics","year":"2011"},{"issue":"16","key":"10.1016\/j.vaccine.2013.11.042_bib0075","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.vaccine.2013.02.011","article-title":"Parental perspectives of vaccine safety and experience of adverse events following immunisation","volume":"31","author":"Parelli","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0080","series-title":"Poster presented at: 29th annual meeting of the European Society for Paediatric Infectious Disease (ESPID)","article-title":"Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup b vaccine (4CMenB) \u2013 exploration of a two dose schedule","author":"Prymula","year":"2011"},{"issue":"9698","key":"10.1016\/j.vaccine.2013.11.042_bib0085","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0090","unstructured":"Novartis Vaccines and Diagnostics S.r.l. BEXSERO [European public assessment report product information]. Siena, Italy, 2012."},{"issue":"(5) May","key":"10.1016\/j.vaccine.2013.11.042_bib0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/OLQ.0b013e318283c8a8","article-title":"Increasing human papillomavirus vaccine acceptability by tailoring messages to young adult women's perceived barriers","volume":"40","author":"Gerend","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ypmed.2010.10.009","article-title":"Exploring pregnant women's views on influenza vaccination and educational text messages","volume":"52","author":"Kharbanda","year":"2011","journal-title":"Prev Med"},{"issue":"8","key":"10.1016\/j.vaccine.2013.11.042_bib0105","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2010.06.020","article-title":"Parents\u2019 decision-making regarding vaccinating their children against influenza: a web-based survey","volume":"32","author":"Flood","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0110","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jadohealth.2005.09.010","article-title":"Improving adolescent health: focus on HPV vaccine acceptance","volume":"37","author":"Zimet","year":"2005","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0115","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archpedi.1995.02170210019003","article-title":"Are children becoming pincushions from immunisation?","volume":"149","author":"Woodlin","year":"1995","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0120","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archfami.3.7.610","article-title":"Too many shots? Parent, nurse and physician attitudes toward multiple simultaneous childhood vaccinations","volume":"3","author":"Madlon-Kay","year":"1994","journal-title":"Arch Fam Med"},{"issue":"(8) August","key":"10.1016\/j.vaccine.2013.11.042_bib0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archpedi.1997.02170450059009","article-title":"Halsey NA Parental knowledge and choice regarding live and inactivated poliovirus vaccines","volume":"151","author":"Thomas","year":"1997","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"10.1016\/j.vaccine.2013.11.042_bib0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0033-3549(04)50049-3","article-title":"Parental attitudes toward multiple poliovirus injections following a provider recommendation","volume":"116","author":"Kolasa","year":"2001","journal-title":"Public Health Rep"},{"key":"10.1016\/j.vaccine.2013.11.042_bib0135","series-title":"ClinicalTrials.gov \u2013 safety and immunogenicity of different meningitis vaccine formulations in adolescents and young adults","author":"United States National Institutes of Health","year":"2013"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13015636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13015636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T17:24:51Z","timestamp":1539019491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13015636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0264410X13015636"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.11.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}